Undiscovered Gems In India Akums Drugs and Pharmaceuticals And 2 Promising Small Caps

In the last week, the Indian market has been flat; however, it has shown significant growth over the past year with a 40% increase and an annual earnings forecast of 17%. In this dynamic environment, identifying promising small-cap stocks like Akums Drugs and Pharmaceuticals can be key to uncovering potential opportunities in India's burgeoning market.

Top 10 Undiscovered Gems With Strong Fundamentals In India

Name	Debt To Equity	Revenue Growth	Earnings Growth	Health Rating
Shree Digvijay Cement	0.01%	13.97%	16.37%	★★★★★★
Vidhi Specialty Food Ingredients	7.27%	11.00%	4.02%	★★★★★★
Le Travenues Technology	10.32%	26.39%	67.32%	★★★★★★
ELANTAS Beck India	NA	14.89%	24.83%	★★★★★★
Timex Group India	14.33%	17.75%	59.68%	★★★★★★
Wealth First Portfolio Managers	4.08%	-43.42%	42.63%	★★★★★☆
Network People Services Technologies	0.11%	84.31%	84.48%	★★★★★☆
Insolation Energy	88.64%	163.87%	419.31%	★★★★★☆
Shree Pushkar Chemicals & Fertilisers	22.85%	17.68%	3.50%	★★★★☆☆
Vasa Denticity	0.11%	38.37%	48.77%	★★★★☆☆

Click here to see the full list of 466 stocks from our Indian Undiscovered Gems With Strong Fundamentals screener.

Here's a peek at a few of the choices from the screener.

Akums Drugs and Pharmaceuticals (NSEI:AKUMS)

Simply Wall St Value Rating: ★★★★★☆

Overview: Akums Drugs and Pharmaceuticals Limited is engaged in the manufacturing and sale of pharmaceutical products and active pharmaceutical ingredients both in India and internationally, with a market capitalization of ₹143.23 billion.

Operations: Akums generates revenue primarily from its CDMO segment, contributing ₹36.32 billion, followed by branded and generic formulations at ₹6.76 billion, and APIs at ₹3.03 billion.

Akums Drugs and Pharmaceuticals, a promising player in India's pharmaceutical scene, has shown resilience with a net debt to equity ratio of 40%, indicating satisfactory leverage. Its interest payments are well covered by EBIT at 9.7x, showcasing strong financial health. Recent developments include an exclusive agreement with Triple Hair Inc., enhancing its market reach in India. The company reported a net income of ₹601.71 million for Q1 2024, reversing from a loss the previous year. With high-quality earnings and strategic partnerships, Akums is poised for impactful growth in the Indian pharmaceutical market.

• Click here and access our complete health analysis report to understand the dynamics of Akums Drugs and Pharmaceuticals.

• Gain insights into Akums Drugs and Pharmaceuticals' historical performance by reviewing our past performance report.

IFB Industries (NSEI:IFBIND)

Simply Wall St Value Rating: ★★★★★☆

Overview: IFB Industries Limited, with a market cap of ₹92.00 billion, operates in the manufacturing and trading of home appliances both in India and internationally.

Operations: The primary revenue stream for IFB Industries comes from its Home Appliances segment, generating ₹36.32 billion. The Engineering division also contributes significantly with ₹8.55 billion in revenue.

IFB Industries, a notable player in the consumer durables sector, has shown impressive earnings growth of 612.7% over the past year, outpacing its industry peers significantly. The company's debt to equity ratio has risen from 11.6% to 22.9% over five years, yet it maintains more cash than total debt and covers interest payments with EBIT at a robust 7.5x coverage. Despite significant insider selling recently, IFB reported net income of ₹375 million for Q1 2024 against a prior year's loss, with sales climbing to ₹12.69 billion from ₹10.86 billion—a promising trajectory for future growth prospects.

• Navigate through the intricacies of IFB Industries with our comprehensive health report here.

• Understand IFB Industries' track record by examining our Past report.

Time Technoplast (NSEI:TIMETECHNO)

Simply Wall St Value Rating: ★★★★★★

Overview: Time Technoplast Limited is involved in the manufacture and sale of polymer and composite products across India and international markets, with a market capitalization of ₹103.07 billion.

Operations: Time Technoplast generates revenue primarily from its Polymer Products segment, contributing ₹33.43 billion, and its Composite Products segment, which adds ₹18 billion.

Time Technoplast, a dynamic player in the packaging sector, showcases robust financial health with its net debt to equity ratio at 25.9%, reflecting prudent management of liabilities. The company has achieved impressive earnings growth of 44.6% over the past year, outpacing the industry average of 8.7%. Its interest payments are well-covered by EBIT at 5.7 times, indicating strong operational efficiency. Recent developments include a dividend increase to INR 2 per share and securing a significant contract worth INR 672 million for CNG storage solutions, underscoring its strategic expansion and shareholder value focus in an evolving market landscape.

• Unlock comprehensive insights into our analysis of Time Technoplast stock in this health report.

• Gain insights into Time Technoplast's past trends and performance with our Past report.

Where To Now?

• Reveal the 466 hidden gems among our Indian Undiscovered Gems With Strong Fundamentals screener with a single click here.
• Are these companies part of your investment strategy? Use Simply Wall St to consolidate your holdings into a portfolio and gain insights with our comprehensive analysis tools.
• Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage.

Curious About Other Options?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com